Skip to main content
. 2018 May 25;56(6):e01626-17. doi: 10.1128/JCM.01626-17

FIG 2.

FIG 2

RVFV and negative-control recombinant proteins used in FMIA. (A) All proteins were analyzed by SDS-PAGE to visualize their integrity. Lane M, molecular size marker (in kilodaltons); lane 1, RVFV Np (32 kDa); lane 2, RVFV Gn (54 kDa); lane 3, RVFV NSs (34 kDa); lane 4, RVFV NSm (30 kDa); lane 5, GFP (37 kDa); lane 6, PCV2 (22 kDa). (B) Western blot analyses were done to confirm the presence of the RVFV proteins. All four RVFV targets were probed with a positive sheep serum. Lane M, molecular size marker (in kilodaltons); lane 1, RVFV Gn; lane 2, RVFV Np; lane 3, RVFV NSs; lane 4, RVFV NSm. (C and D) RVFV proteins Np and Gn were further tested against monoclonal antibodies. (C) Monoclonal antibody MAB240P was used against Np. Lane 1, RVFV Np; lane 2, RVFV Gn. (D) Monoclonal antibody NR43190 was used against Gn. Lane 1, RVFV Gn; lane 2, RVFV Np.